INT57360

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.66
First Reported 1994
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 31
Total Number 31
Disease Relevance 12.72
Pain Relevance 2.24

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (STAR) transport (STAR) mitochondrion (STAR)
small molecule metabolic process (STAR)
Anatomy Link Frequency
plasma 2
blood 2
tibialis anterior 2
knee 2
dorsal 1
STAR (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 37 99.96 Very High Very High Very High
Adalimumab 4 99.28 Very High Very High Very High
Arthritis 22 98.28 Very High Very High Very High
Inflammation 48 97.84 Very High Very High Very High
Angina 3 96.28 Very High Very High Very High
Pain 258 95.96 Very High Very High Very High
psoriasis 1 81.96 Quite High
corticosteroid 1 79.44 Quite High
cINOD 15 77.28 Quite High
Analgesic 1 76.68 Quite High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 185 100.00 Very High Very High Very High
Rheumatoid Arthritis 40 99.96 Very High Very High Very High
Hypertension 33 99.88 Very High Very High Very High
Hyperlipidemia 14 99.80 Very High Very High Very High
Hyperglycemia 60 99.60 Very High Very High Very High
Diabetes Mellitus 1302 99.44 Very High Very High Very High
Bacteremia 2 99.42 Very High Very High Very High
Coronary Artery Disease 20 99.30 Very High Very High Very High
Obesity 125 99.16 Very High Very High Very High
Flushing 1 99.16 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Gene_expression (results) of STAR associated with necrosis, cancer, rheumatoid arthritis, adalimumab and arthritis
1) Confidence 0.66 Published 2003 Journal J. Rheumatol. Section Title Doc Link 14719195 Disease Relevance 0.67 Pain Relevance 0.58
Following washes with PBC, cells were incubated with rabbit anti-mouse FITC (STAR 9B, Serotec, UK) at 1?
Gene_expression (incubated) of STAR
2) Confidence 0.65 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2941452 Disease Relevance 0.12 Pain Relevance 0
[Short- and mid-term results with the STAR total ankle prosthesis].
Gene_expression (prosthesis) of STAR in ankle
3) Confidence 0.65 Published 1999 Journal Orthopade Section Title Doc Link 10525690 Disease Relevance 0.87 Pain Relevance 0.25
The rate of transfer of 7DHC by N-62 StAR protein was comparable to rate of cholesterol transfer by this carrier.
Gene_expression (transfer) of StAR
4) Confidence 0.65 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2629546 Disease Relevance 0.06 Pain Relevance 0
Studies with purified enzymes show that StAR protein likely transports 7DHC to the inner mitochondrial membrane, that 7DHC can compete effectively with cholesterol for the substrate binding site on P450scc and that the catalytic efficiency of 3?
Gene_expression (protein) of StAR
5) Confidence 0.65 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2629546 Disease Relevance 0.05 Pain Relevance 0
Three out of 17 patients with Staphylococcus aureus bacteremia had significantly increased anti-STAR antibody levels (150, 75 and 75 micrograms/ml), and STAR neutralizing activities (2.2, 3.6 and 4.1 micrograms STAR neutralized per ml plasma, respectively).
Gene_expression (levels) of anti-STAR in plasma associated with bacteremia
6) Confidence 0.58 Published 1994 Journal Thromb. Haemost. Section Abstract Doc Link 8165631 Disease Relevance 0.28 Pain Relevance 0.10
Three out of 17 patients with Staphylococcus aureus bacteremia had significantly increased anti-STAR antibody levels (150, 75 and 75 micrograms/ml), and STAR neutralizing activities (2.2, 3.6 and 4.1 micrograms STAR neutralized per ml plasma, respectively).
Gene_expression (levels) of STAR in plasma associated with bacteremia
7) Confidence 0.58 Published 1994 Journal Thromb. Haemost. Section Abstract Doc Link 8165631 Disease Relevance 0.29 Pain Relevance 0.10
Glyphosate disrupts steroidogenic acute regulatory (StAR) protein expression across diverse taxonomic groups, which modulates the initial step in the steroidogenic pathway (Walsh et al. 2000) and leads to reductions in steroid hormone production, including both testosterone and E2.
Gene_expression (expression) of StAR
8) Confidence 0.16 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2592273 Disease Relevance 0.31 Pain Relevance 0
The structure of the START domain differs from the Bet v 1 structure by an N-terminal extension consisting of an ?
Gene_expression (structure) of START
9) Confidence 0.12 Published 2008 Journal BMC Evol Biol Section Body Doc Link PMC2577659 Disease Relevance 0 Pain Relevance 0
The main symptom reported in the START position during PF/SLR was tingling (14.0%).
Gene_expression (position) of START
10) Confidence 0.11 Published 2010 Journal BMC Neurol Section Body Doc Link PMC2940775 Disease Relevance 0.32 Pain Relevance 0.17
Between tests comparisons identified a significantly higher tibialis anterior muscle activation at the START position during DF/SLR compared to PF/SLR (p < 0.001) (Table 2).
Gene_expression (position) of START in tibialis anterior
11) Confidence 0.11 Published 2010 Journal BMC Neurol Section Body Doc Link PMC2940775 Disease Relevance 0 Pain Relevance 0
During DF/SLR the mean intensity went from 0.8 ± 1.5 at the START position to 3.0 ± 1.8 at P1 and to 6.8 ± 2.0 at P2 (p < 0.001 both).
Gene_expression (position) of START
12) Confidence 0.11 Published 2010 Journal BMC Neurol Section Body Doc Link PMC2940775 Disease Relevance 0 Pain Relevance 0
The tester placed the subject's knee in full extension (defined as end range resistance) and the subject was instructed to indicate this start position (START) by pressing the hand held trigger.
Gene_expression (position) of START in knee
13) Confidence 0.11 Published 2010 Journal BMC Neurol Section Body Doc Link PMC2940775 Disease Relevance 0 Pain Relevance 0
Using the conservative threshold of 1.5-fold increase over resting levels, no muscle activity was triggered at the START position, P1 or P2 during PF/SLR.
Gene_expression (position) of START in muscle
14) Confidence 0.11 Published 2010 Journal BMC Neurol Section Body Doc Link PMC2940775 Disease Relevance 0.13 Pain Relevance 0
There was no difference in mean intensity between PF/SLR and DF/SLR at the START position, P2 or rest after SLR.
Gene_expression (position) of START
15) Confidence 0.11 Published 2010 Journal BMC Neurol Section Body Doc Link PMC2940775 Disease Relevance 0 Pain Relevance 0
With the addition of ankle dorsiflexion (DF/SLR) there was an increase in the frequency of reported movement induced symptoms (not present at START position) at P1 by 16.2% in the posterior thigh compared to PF/SLR.
Neg (not) Gene_expression (position) of START in thigh
16) Confidence 0.11 Published 2010 Journal BMC Neurol Section Body Doc Link PMC2940775 Disease Relevance 0 Pain Relevance 0
The mean symptom intensity at the START position was 0.7 ± 1.4 during PF/SLR (Figure 1B).
Gene_expression (position) of START
17) Confidence 0.11 Published 2010 Journal BMC Neurol Section Body Doc Link PMC2940775 Disease Relevance 0 Pain Relevance 0
At the START position 58.1% of the subjects reported no symptoms during PF/SLR (Figure 4A).
Gene_expression (position) of START
18) Confidence 0.10 Published 2010 Journal BMC Neurol Section Body Doc Link PMC2940775 Disease Relevance 0.29 Pain Relevance 0.15
One possible explanation for the activation of the tibialis anterior is related to the START position for this DF/SLR test which included fixation in a customized brace.
Gene_expression (position) of START in tibialis anterior
19) Confidence 0.10 Published 2010 Journal BMC Neurol Section Body Doc Link PMC2940775 Disease Relevance 0.29 Pain Relevance 0.09
At the START position, people with T2DM frequently reported symptoms associated with neurogenic sources, such as numbness and tingling, which were not present in healthy individuals.
Gene_expression (position) of START associated with hypesthesia and diabetes mellitus
20) Confidence 0.10 Published 2010 Journal BMC Neurol Section Body Doc Link PMC2940775 Disease Relevance 1.17 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox